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Comparison of G-to-A mutation frequencies induced by
APOBEC3 proteins in H9 cells and peripheral blood
mononuclear cells in the context of impaired processivities of
drug-resistant human immunodeficiency virus type 1 reverse
transcriptase variants
Abstract
APOBEC3 proteins can inhibit human immunodeficiency virus type 1 (HIV-1) replication by inducing
G-to-A mutations in newly synthesized viral DNA. However, HIV-1 is able to overcome the
antiretroviral activity of some of those enzymes by the viral protein Vif. We investigated the impact of
different processivities of HIV-1 reverse transcriptases (RT) on the frequencies of G-to-A mutations
introduced by APOBEC3 proteins. Wild-type RT or the M184V, M184I, and K65R+M184V RT
variants, which are increasingly impaired in their processivities, were used in the context of a
vif-deficient molecular HIV-1 clone to infect H9 cells and peripheral blood mononuclear cells
(PBMCs). After two rounds of infection, a part of the HIV-1 env gene was amplified, cloned, and
sequenced. The M184V mutation led to G-to-A mutation frequencies that were similar to those of the
wild-type RT in H9 cells and PBMCs. The frequencies of G-to-A mutations were increased after
infection with the M184I virus variant. This effect was augmented when using the K65R+M184V virus
variant (P < 0.001). Overall, the G-to-A mutation frequencies were lower in PBMCs than in H9 cells.
Remarkably, 38% +/- 18% (mean +/- standard deviation) of the env clones derived from PBMCs did not
harbor any G-to-A mutation. This was rarely observed in H9 cells (3% +/- 3%). Our data imply that the
frequency of G-to-A mutations induced by APOBEC3 proteins can be influenced by the processivities
of HIV-1 RT variants. The high number of nonmutated clones derived from PBMCs leads to several
hypotheses, including that additional antiretroviral mechanisms of APOBEC3 proteins other than their
deamination activity might be involved in the inhibition of vif-deficient viruses.
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APOBEC3 proteins can inhibit human immunodeficiency virus type 1 (HIV-1) replication by inducing
G-to-A mutations in newly synthesized viral DNA. However, HIV-1 is able to overcome the antiretroviral
activity of some of those enzymes by the viral protein Vif. We investigated the impact of different processivities
of HIV-1 reverse transcriptases (RT) on the frequencies of G-to-A mutations introduced by APOBEC3 proteins.
Wild-type RT or the M184V, M184I, and K65RM184V RT variants, which are increasingly impaired in their
processivities, were used in the context of a vif-deficient molecular HIV-1 clone to infect H9 cells and peripheral
blood mononuclear cells (PBMCs). After two rounds of infection, a part of the HIV-1 env gene was amplified,
cloned, and sequenced. The M184V mutation led to G-to-A mutation frequencies that were similar to those of
the wild-type RT in H9 cells and PBMCs. The frequencies of G-to-A mutations were increased after infection
with the M184I virus variant. This effect was augmented when using the K65RM184V virus variant (P <
0.001). Overall, the G-to-A mutation frequencies were lower in PBMCs than in H9 cells. Remarkably, 38% 
18% (mean  standard deviation) of the env clones derived from PBMCs did not harbor any G-to-A mutation.
This was rarely observed in H9 cells (3%  3%). Our data imply that the frequency of G-to-A mutations
induced by APOBEC3 proteins can be influenced by the processivities of HIV-1 RT variants. The high number
of nonmutated clones derived from PBMCs leads to several hypotheses, including that additional antiretroviral
mechanisms of APOBEC3 proteins other than their deamination activity might be involved in the inhibition
of vif-deficient viruses.
Proteins of the APOBEC3 (apolipoprotein B mRNA-
editing enzyme, catalytic polypeptide 3) family, especially
APOBEC3G and, to a lesser extent, APOBEC3F, have been
identified as host factors which can inhibit the replication of
human immunodeficiency virus type 1 (HIV-1) and belong to
an intrinsic defense system (6, 37, 57, 68, 72). They are ex-
pressed in several cell lines, as well as primary cells like CD4
T cells and macrophages (12, 57). The HIV-1 protein Vif
suppresses the intrinsic antiretroviral effect by binding to
APOBEC3G, which results in the degradation of APOBEC3G
by the proteasome (38, 43, 58, 60). In the absence of Vif,
APOBEC3G and APOBEC3F are packaged into virions
through interactions with HIV-1 Gag and/or viral RNA (1,
9, 27, 28, 39, 53, 63, 68, 70).
Several antiretroviral mechanisms of APOBEC3 proteins
have been proposed (reviewed in references 11 and 20). One
antiretroviral mechanism of those proteins is their ability to
deaminate cytosine residues in single-stranded HIV-1 DNA
during reverse transcription, leading to G-to-A hypermutation
in the viral plus strand (18, 35, 41, 42, 71). Here, APOBEC3F
leads preferentially to G-to-A mutation in the context of GA
dinucleotides (7, 37, 68), and GG dinucleotides are target sites
specific for APOBEC3G, leading to GG-to-AG mutations (6,
18, 37, 68, 69). This process is time dependent, and thus, a
533 G-to-A mutational gradient is generated in the viral
genome in correlation to the exposure time of single-stranded
viral DNA to APOBEC3G/F (10, 61, 69). Single-stranded viral
DNA is generated during reverse transcription from an RNA-
DNA hybrid by the viral RNaseH domain of the HIV-1 reverse
transcriptase (RT), and this activity of HIV-1 RNaseH leads to
the activation of APOBEC3G (59). APOBEC3G can deami-
nate cytosine residues independently of the HIV-1 RT in a
cell-free deamination assay (62); however, the progression of
the synthesis of double-stranded viral DNA terminates the
deamination process of APOBEC3 proteins, thereby resulting
in the described 533 G-to-A mutational gradient.
Thus, it is conceivable that the HIV-1 RT is influencing the
G-to-A mutation frequency induced by APOBEC3 proteins.
Here, we investigated the impact of HIV-1 RT variants differ-
ing in their processivities, defined as the number of nucleotides
added to a template prior to dissociation of the enzyme from
its template, on the G-to-A mutation frequencies induced by
APOBEC3 proteins. We hypothesized that reduced processivi-
ties lead to an increase of the G-to-A mutation frequencies
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induced by APOBEC3 proteins, because the time period dur-
ing which the target viral DNA remains single stranded is
prolonged. The rate of polymerization correlates with the pro-
cessivity (3, 56). Very recently, it has been shown that defects
in the rate of polymerization and processivities of M184 vari-
ants of HIV-1 RT are both due to defects in deoxynucleoside
triphosphate (dNTP) utilization (16). For our approach, we
have chosen the RT variants carrying the M184V, M184I, or
the K65RM184V mutations, which confer resistance to cer-
tain nucleoside/nucleotide RT inhibitors. Viruses harboring
these mutations at codon 184 of the RT are resistant to the RT
inhibitors lamivudine and emtricitabine (8, 54, 55). The
M184V mutation causes a decrease of the processivity (3, 56),
which is even further impaired by RT variants carrying the
M184I mutation (3). The additional introduction of the K65R
mutation, which confers resistance to tenofovir and abacavir
(47), further reduces the processivity of the M184V RT variant
(13, 67).
The deaminase activities of APOBEC3G/F and the G-
to-A mutation frequencies and pattern have predominantly
been studied in T-cell lines, partially using exogenous
APOBEC3G/F (18, 35, 41, 42, 68, 71). Only recently has the
deaminase activity of endogenous APOBEC3G of several T-
cell lines and primary CD4 T cells been compared with ex-
ogenous APOBEC3G derived from APOBEC3G-transfected
epithelial cell lines, showing that endogenous APOBEC3G
expresses a significantly lower deaminase activity than exoge-
nous APOBEC3G (64). In our study, we determined the G-
to-A mutation frequencies of endogenous APOBEC3 proteins
in peripheral blood mononuclear cells (PBMCs) in comparison
to these mutation frequencies in H9 cells in the context of
vif-negative viruses harboring different RT variants in order to
gain more insight into the deamination process in physiological
target cells of HIV-1.
(This work was presented in part at the Deutsch-O¨sterreich-
ischer AIDS Kongreß, June 27 to 30, 2007, Frankfurt, Ger-
many [30]; Third European Congress of Virology, September 2
to 5, 2007, Nuremberg, Germany [31]; and 15th Conference on
Retroviruses and Opportunistic Infections, February 3 to 6,
2008, Boston, MA [32]).
MATERIALS AND METHODS
Plasmids. The RT mutations M184V and M184I were separately introduced
into the molecular HIV-1 clone pNL4-3 (obtained through the AIDS Research
and Reference Reagent Program, Division of AIDS, National Institute of Al-
lergy and Infectious Diseases [NIAID], National Institutes of Health [NIH],
Bethesda, MD, from Malcolm Martin) as previously described (21). The HIV-1
clone pNL4-3vif was kindly provided by Klaus Strebel, NIH, NIAID (25). The
M184V and M184I mutations were introduced into this plasmid by restriction
with Sph1 and Age1 (New England Biolabs, Frankfurt, Germany), and subse-
quent ligation using 1 U T4 DNA ligase (Invitrogen, Karlsruhe, Germany). The
K65R mutation was introduced into pNL4-3M184V and pNL4-3vifM184V by
site-directed mutagenesis (QuikChange XL site-directed mutagenesis kit; Strat-
agene, La Jolla, CA) using the mutagenesis oligonucleotides sdm K65R (5-CT
CCAGTATTTGCCATAAAGAGAAAAGACAGTACTAAATGGAG-3) and
sdm K65Rrc (5-CTCCATTTAGTACTGTCTTTTCTCTTTATGGCAAATAC
TGGAG-3) (introduced mutation is underlined) following the manufacturer’s
instructions. The mutations were confirmed by sequence analysis.
Virus stocks. Amounts of 3  106 293T cells were separately transfected with
pNL4-3 or pNL4-3vif encoding wild-type RT or the M184V, M184I, or
K65RM184V variants, respectively. After 48 h, supernatants were collected,
centrifuged at 2,000  g at room temperature for 5 min to pellet cell debris, and
finally digested with 10 U DNase I/500 l (Boehringer, Mannheim, Germany) at
25°C for 30 min to avoid possible carryover of plasmids. Virus stocks were stored
at 80°C. For characterization, viral RNA of each virus stock was isolated by
using a NucleoSpin RNA virus kit (Macherey Nagel, Dueren, Germany) accord-
ing to the manufacturer’s instructions. cDNA synthesis was performed by using
random hexamers and Moloney murine leukemia virus RT (Invitrogen) accord-
ing to the manufacturer’s instructions. To evaluate the virus titer, quantitative
real-time PCR was performed with the reaction mixture containing 10 l cDNA,
1 ROX PCR buffer (46), 3.5 mM MgCl2, 0.5 mM dNTPs, 0.4 M each of the
oligonucleotides pol 2981 (5-TCAGTACAATGTGCTTCCACAGG-3) and
pol 3206 rc (5-TTTGTCTGGTGTGGTAAATCCCCAC-3), with Taq DNA
polymerase in a final volume of 50 l. Amplification was performed for 50 cycles
(94°C for 30 s, 55°C for 30 s, and 72°C for 30 s) in an Applied Biosystems 7700
Prism spectrofluorometric thermal cycler (Applied Biosystems, Foster City, CA).
The oligonucleotides were based on the HIV-1 NL4-3 and HIV-1 HXB2 se-
quences (GenBank accession numbers AF324493 and K03455, respectively) and
synthesized by biomers.net (Ulm, Germany).
Cells and infections. The T-cell lines H9 and MT4 were maintained under
standard conditions. Briefly, cells were cultured in RPMI 1640 medium supple-
mented with 10% heat-inactivated fetal bovine serum (Invitrogen), 2 mM glu-
tamine, 170 mM penicillin, and 40 mM streptomycin at 37°C and 5% CO2.
PBMCs were isolated from buffy coats obtained from healthy donors (Transfu-
sionsmedizin, Suhl, Germany) by using a Ficoll-Hypaque (Sigma, Munich, Ger-
many) gradient. After isolation, cells were washed twice, counted, and trans-
ferred into complete RPMI 1640 medium at a density of 3 106 cells/ml. PBMCs
were stimulated with 3 g/ml phytohemagglutinin (Sigma). An amount of 10
U/ml interleukin-2 (obtained through the AIDS Research and Reference Re-
agent Program, Division of AIDS, NIAID, NIH, from Hoffmann-La Roche, Inc.)
was added after 24 h to the cell culture and maintained in the medium. After an
additional 48 h, the phytohemagglutinin was removed by washing the cells twice.
H9 cells (1  106) or PBMCs (3  106) (72 h after isolation) were infected with
each virus stock by spinoculation (48), washed twice, and resuspended in 1 ml
medium. At 36 to 48 h postinfection, the supernatants were harvested, centri-
fuged, and used for a second round of infection, which was carried out as
described above. Cells were harvested 6 h later and stored at20°C until further
analyses. To test the replication abilities of the different virus variants, 1  106
H9 cells and MT4 cells were infected by spinoculation with the same quantity of
all HIV-1 NL4-3 variants as defined by HIV-1 RNA copy numbers, i.e., 1  109
HIV-1 RNA copies were used. Cells were washed twice after infection, super-
natants were collected daily or every second day for 5 days after infection, and an
in-house p24 enzyme-linked immunosorbent assay was performed as previously
described (45).
Viral DNA isolation and sequences. Total DNA of infected cells was isolated
by using a NucleoSpin blood kit (Macherey-Nagel) in accordance with the man-
ufacturer’s instructions, and DNA was eluted in 130 l elution buffer (5 mM
Tris-HCl, pH 8.5). The DNA was controlled in several ways. First, part of the
-actin gene was amplified to control for the presence of cellular DNA. Briefly,
PCR was performed using 1 PCR buffer, 2 mM MgCl2, 0.5 mM dNTPs, 0.4 M
of each of the oligonucleotides bact 532 (5-CCATCTACGAGGGGTATGC-3)
and bact 728 rc (5-CGTGGCCATCTCTTGCTC-3) (-actin; GenBank acces-
sion number X00351), and Taq DNA polymerase in a final volume of 50 l. DNA
was amplified in 35 cycles (94°C for 30 s, 57°C for 30 s, and 72°C for 30 s) with
a termination of 5 min at 72°C in a Mastercycler gradient thermocycler (Eppen-
dorf, Hamburg, Germany). Second, PCR for the discrimination between vif-
positive and vif-negative DNA was performed using the same conditions de-
scribed above and the HIV-1 oligonucleotides int 4962 (5-GGTGAAGGGGC
AGTAGTAATAC-3) and vpr 5685 rc (5-CCTAAGTTATGGAGCCATATC
CTAG-3). All amplification products were analyzed by gel electrophoresis.
Third, M184V, M184I, and K65R allele-specific real-time PCRs were conducted
to exclude contaminations between the variants used, as previously described (2,
46). The K65R allele-specific PCR was performed accordingly using the primers
pol 2835 rc (5-GTGGTATTCCTAATTGAACTTCCC-3) and IN K65 (5-TC
CAGTATTTGCCATAAAGIA-3) or IN K65R (5-CCAGTATTTGCCATAA
AGIG-3), respectively (I, inosine). Fourth, contamination by full-length HIV-1
plasmids was ruled out by amplification of the plasmid-specific sequence span-
ning parts of the HIV-1 5 long terminal repeat (LTR) and the cloned human
genomic DNA. The PCR was carried out according to the conditions described
above by using the oligonucleotide LTR 611 (5-AGTCAGTGTGGAAAATCT
CTAGC-3) plus the pNL4-3-genomic rc (5-TCTTGTGGTATCAGAGTAGA
GG-3) and an annealing temperature of 55°C. All oligonucleotides were syn-
thesized by biomers.net.
To examine the G-to-A mutation frequencies of viral DNA extracted from
infected H9 cells or PBMCs, high-fidelity PCR was performed either by using a
Triple Master PCR system (Eppendorf) or an EasyA kit (Stratagene). A part of
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the HIV-1 env gene was amplified by using the oligonucleotides BamHI/EcoRI
env 7045 (5-GGATCCGAATTCCTGCCAATTTCACAGACAATGC-3) and
ApaI/XhoI env 7552 rc (5-GGGCCCCTCGAGCACATTTGTCCACTGATG
GGAGG-3) following the manufacturer’s instructions. Amplicons were purified
by using a NucleoSpin extract II kit (Macherey-Nagel), eluted in 20 l elution
buffer (5 mM Tris-HCl, pH 8.5), and cloned into the TA cloning vector provided
in a StrataClone PCR cloning kit (Stratagene) in accordance with the manufac-
turer’s instructions. Plasmids were isolated and sequenced by using the oligonu-
cleotides M13 forward (5-GTAAAACGACGGCCAG-3) and M13 reverse (5-
CAGGAAACAGCTATGAC-3), a BigDye terminator cycle sequencing kit,
version 3.1, and an ABI 3100 sequencer (Applied Biosystems). Sequences were
analyzed with Edit View 3.7 NT (Applied Biosystems) and Vector NTI suite 7
(Invitrogen). G-to-A mutations were analyzed by using the program Hypermut
2.0 that is freely available at http://www.hiv.lanl.gov/content/sequence/HYPERMUT
/hypermut.html (52).
Statistical analysis. Differences in the G-to-A mutation frequencies were
analyzed for statistical significance by using the two-tailed Mann-Whitney test. A
P value of 0.05 was considered a significant difference between two groups.
RESULTS
Replication kinetics of HIV-1 NL4-3 and HIV-1 NL4-3vif
harboring different RT variants in H9 and MT4 cells. To
determine the impact of differences in the processivities of
HIV-1 RT on the G-to-A mutation frequencies induced by
APOBEC3 proteins, we introduced several mutations into the
RT gene of the HIV-1 clones pNL4-3 and pNL4-3vif. Virus
stocks of all variants were generated and tested with regard to
their replication abilities. First, we infected nonpermissive H9
cells, which express APOBEC3G/F and, therefore, inhibit the
replication of HIV-1 NL4-3vif variants. None of the HIV-1
NL4-3vif viruses replicated in H9 cells, whereas HIV-1
NL4-3, HIV-1 NL4-3M184V, and HIV-1 NL4-3M184I showed
similar replication abilities (Fig. 1A). Next, we infected per-
missive MT4 cells, which do not express APOBEC3G/F, and
thus, both vif-positive and vif-negative HIV-1 variants could
replicate in those cells (17). The replication abilities of all eight
HIV-1 NL4-3 and vif variants were similar in MT4 cells (Fig.
1B). As expected, HIV-1 NL4-3 variants were able to replicate
in both cell lines, whereas HIV-1 NL4-3vif variants could
only replicate in MT4 cells.
Lack of differences in total mutation frequencies of HIV-1
NL4-3 carrying different RT variants in infected H9 cells and
PBMCs. It has been reported that the processivities of HIV-1
RT variants are inversely correlated to their fidelities, i.e.,
slower enzymes introduce fewer mutations (reviewed in refer-
ence 51). To account for those differences in mutation frequen-
cies in the following experiments with the HIV-1 NL4-3vif
viruses, we investigated the frequencies of mutations of the
HIV-1 NL4-3 variants containing vif. Thus, the impact of
APOBEC3 proteins on the mutation frequencies is precluded.
Two independent experiments were performed using H9 cells,
and another two independent experiments with PBMCs from
donors A and B, and the results are summarized in Fig. 2 and
Table 1. In H9 cells infected with HIV-1 NL4-3, HIV-1 NL4-
3M184V, and HIV-1 NL4-3M184I, no mutations in the env se-
quences were observed in approximately 50% (48 to 57%) of
clones. The majority of mutated clones harbored only one
mutation (36 to 39%), clones carrying two or three mutations
were infrequently observed, and the maximum of four muta-
tions was only detected in one of 80 clones (Fig. 2A). G-to-A
mutations were observed in seven clones, each carrying one
G-to-A mutation. There were no significant differences ob-
served between the mutation frequencies regarding the three
different viral variants. In total, 53 mutations in 80 clones were
observed; 7 of 53 mutations were G-to-A changes (Fig. 2B).
Remarkably, A-to-G mutations were the most-frequently de-
tected (24/53), followed by T-to-C mutations (12/53) (Fig. 2B).
Similar results were obtained from the infection of PBMCs
from donors A and B with those viruses. Forty-six to 83% of
clones did not show any mutation, 16 to 27% harbored one
mutation, and 9 to 21% carried two or three mutations (Fig.
2A). In comparing the mutation frequencies of the four viral
variants HIV-1 NL4-3, HIV-1 NL4-3M184V, HIV-1 NL4-
3M184I, and HIV-1 NL4-3K65RM184V, no significant differ-
ences were observed. In addition, the mutation frequencies in
H9 cells (0.13% 	 0.04% [mean 	 standard deviation]) and
PBMCs (0.20% 	 0.11%) revealed no significant differences
(Table 1). In total, 43 env clones derived from infected PBMCs
were analyzed and 36 mutations were detected. As seen in env
sequences derived from infected H9 cells, A-to-G transitions
were frequently detected (Fig. 2B). More than 50% of all
mutations were G-to-A changes (19/36) (Fig. 2B). However,
this includes one single clone obtained from PBMCs infected
with HIV-1 NL4-3M184V, which, in contrast to the other 35
clones, exhibited G-to-A hypermutation. In this clone, we de-
tected 11 G-to-A mutations; 7 of those occurred within GG
dinucleotides (GG to AG), which is the target site specific for
FIG. 1. Replication kinetics of HIV-1 NL4-3 and HIV-1 NL4-3vif
harboring different RT variants in H9 and MT4 cells. Shown are the
results of a representative example of three independent experiments.
Supernatants from uninfected cells served as negative controls and are
indicated by crosses. (A) H9 cells were infected with HIV-1 NL4-3
(black squares), HIV-1 NL4-3M184V (black circles), HIV-1 NL4-3M184I
(black diamonds), HIV-1 NL4-3vif (open squares), HIV-1 NL4-
3vifM184V (open circles), and HIV-1 NL4-3vifM184I (open dia-
monds). (B) MT4 cells were infected with all six HIV-1 variants listed
above, HIV-1 NL4-3K65RM184V (black triangles), and HIV-1 NL4-
3vifK65RM184V (open triangles). Supernatants were collected daily or
every second day and assayed for viral p24 antigen by enzyme-linked
immunosorbent assay.
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APOBEC3G (6, 18, 37, 68, 69) (Fig. 2A). As this result is very
unusual in the presence of Vif, all DNA samples isolated after
the second round of infection were controlled by real-time
PCRs specific for RT mutant alleles and PCRs specific for
wild-type vif and vif-deficient DNA, as well as pNL4-3 vector-
specific PCRs. No contamination was observed (data not
shown). This suggests that in rare events, APOBEC3-induced
G-to-A hypermutation can occur despite the presence of Vif.
Increase of G-to-A mutation frequency of viral DNA in H9
cells infected with HIV-1 NL4-3vifM184I. To determine the
impact of each RT variant on the G-to-A mutation frequency
induced by APOBEC3G/F, we infected H9 cells with HIV-1
NL4-3vif and its variants HIV-1 NL4-3vifM184V and HIV-1
NL4-3vifM184I in two independent experiments. A total of 99
clones were analyzed (Fig. 3; Table 1). Three clones harbored
no G-to-A mutations. Two clones from the remaining 96
clones harboring G-to-A mutations were identical. Thus, one
of those two clones was excluded from the final analysis to
avoid any unwanted bias due to possible clonal amplification.
All 31 individual env sequences derived from HIV-1 NL4-
3vif infected H9 cells harbored G-to-A mutations (Fig. 3A).
Eighteen of 31 clones (58.1%) carried one to eight and 13 of 31
clones (31.9%) nine and more G-to-A mutations. A maximum
of 18 G-to-A mutations was found in one clone, i.e., 19.8% of
all guanine residues were mutated in this sequence. A similar
pattern was observed in the 34 env sequences derived from H9
cells infected with HIV-1 NL4-3vifM184V. Eight of 34 clones
(23.5%) harbored nine and more G-to-A mutations, with a
maximum of 19 G-to-A mutations in one clone; 24 of 34 clones
(70.6%) carried one to eight G-to-A mutations, and no G-to-A
changes were observed in two clones (Fig. 3A). Taken to-
gether, we observed no significant differences between those
two viruses (Fig. 3C).
In contrast, the infection of H9 cells with HIV-1 NL4-
3vifM184I led to an increased frequency of G-to-A mutations.
In one clone, no G-to-A mutations were observed, and 15 of 33
clones (45.5%) harbored one to eight G-to-A mutations. Sev-
enteen of 33 env sequences (51.5%) carried nine and more
G-to-A mutations (Fig. 3A). In four of those clones, 22, 23, 24,
and 40 of 91 guanine residues (24.2 to 44.0%), respectively,
were mutated to adenine. These results differ significantly from
the G-to-A mutation frequency observed in H9 cells infected
with HIV-1 NL4-3vifM184V (P 
 0.04) (Fig. 3C). Although
the infection of H9 cells with HIV-1 NL4-3vifM184I led to
more G-to-A mutations than infection with HIV-1 NL4-3vif,
those differences were not significant (P 
 0.24) (Fig. 3C).
As already seen in the results for H9 cells infected with
vif-positive HIV-1 NL4-3 variants, the most-frequently ob-
served non-G-to-A mutations were A-to-G and T-to-C muta-
tions (Fig. 3B). No differences in the non-G-to-A mutation
frequencies or patterns in regard to the different HIV-1 NL4-3
variants were observed.
Inverse correlation between processivities of RTs and G-
to-A mutation frequencies of viral DNA in PBMCs infected
with HIV-1 NL4-3vif variants. It has been shown that the
replication capacities of HIV-1 variants differing in the 184th
amino acid position of the RT are very similar in T-cell lines,
suggesting that the differences in the processivities of those RT
variants may not delay substantially the process of reverse
transcription in HIV-1-infected T-cell lines (3). However, a
FIG. 2. Total mutation frequencies of viral DNA do not differ in
H9 cells and PBMCs infected with HIV-1 NL4-3 harboring different
RT variants. (A) H9 cells and PBMCs were infected with HIV-1 NL4-3
containing vif and the different RT variants, wild-type RT, M184V,
M184I, and K65RM184V. After the second round of infection, viral
DNA was isolated and 466 nucleotides of the env gene were amplified,
cloned, and sequenced. The percentages of HIV-1 env clones carrying
the indicated numbers of mutations are shown. The numbers of clones
analyzed are given. Two independent experiments using H9 cells were
performed, and PBMCs from two different donors, A and B, were
used. The infection with HIV-1 NL4-3K65RM184V was only performed
in PBMCs from donor B. (B) Preferences of nucleotide substitutions in
HIV-1 env clones in H9 cells and PBMCs infected with HIV-1 NL4-3
harboring the different RT variants. The total numbers of mutations
are indicated.
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correlation between the processivities of those RT variants and
their replication abilities has been observed in PBMCs (3).
This underlines the role of this effect in vivo, and thus, we
expanded our experiments and investigated the impact of dif-
ferent RT variants on the G-to-A mutation frequencies in
PBMCs (the physiological target cells of HIV-1) from four
different HIV-1-negative donors. In addition, we included
HIV-1 NL4-3vifK65RM184V, which exhibits a lower proces-
sivity than the M184V RT variant (13, 67), to broaden the
spectrum of RT variants with reduced processivities.
In total, 363 HIV-1 env clones were sequenced and analyzed.
Two hundred three clones showed at least one G-to-A muta-
tion. In order to avoid any unwanted bias due to possible clonal
amplification, 22 of those 203 clones were excluded from the
final analysis, because identical clones derived from the same
cell cultures were detected. Thus, 341 clones were included in
the final analysis (Fig. 3; Table 1). Forty-nine of 78 clones
derived from PBMCs infected with HIV-1 NL4-3vif showed
G-to-A mutations. Nearly all of those HIV-1 env sequences
harbored 1 to 7 G-to-A mutations, only one clone showed 9
mutations, and two clones showed 11 G-to-A mutations (Fig.
3A). A similar pattern was observed in HIV-1 env clones de-
rived from PBMCs infected with HIV-1 NL4-3vifM184V.
Sixty-five of 105 HIV-1 env sequences carried G-to-A muta-
tions. The majority of those clones showed one to seven G-
to-A changes (81.8 to 100%). Eight, 9, 12, and 13 G-to-A
mutations were observed once, and 10 or 11 G-to-A mutations
twice. HIV-1 env sequences derived from PBMCs infected with
HIV-1 NL4-3vifM184I showed higher G-to-A mutation fre-
quencies than those infected with clones of HIV-1 NL4-3vif
and HIV-1 NL4-3vifM184V; however, this increase was not
significant (P
 0.06 and P
 0.09, respectively). Here, 57 of 90
clones revealed G-to-A mutations, with 33 of 57 clones
(57.9%) harboring one to seven and 20 clones nine G-to-A
mutations. In contrast to the other two previously described
HIV-1 RT variants, we detected eight clones with 14 to 18
G-to-A mutations; one clone even carried 38 G-to-A muta-
tions, i.e., 41.8% of all guanine residues were mutated to ad-
enine. Such a highly mutated sequence was also observed once
in H9 cells infected with the same HIV-1 variant, NL4-
3vifM184I. The HIV-1 variant NL4-3vifK65RM184V was used
to infect PBMCs from donors B, C, and D (Fig. 3A). In 68
clones analyzed, we detected 32 HIV-1 env sequences with
G-to-A mutations. Here, only 15 of 32 clones (46.9%) carried
one to seven G-to-A mutations. Seventeen of 32 clones
(53.1%) harbored 9 to 16 G-to-A mutations (Fig. 3; Table 1).
Thus, HIV-1 NL4-3vifK65RM184V showed the highest G-
to-A mutation frequency, which differed significantly from the
mutation frequencies of HIV-1 NL4-3vif and HIV-1 NL4-
3vifM184V (P  0.001) (Fig. 3C).
In regard to non-G-to-A mutations, we observed frequencies
and distributions that were similar to those of HIV-1 env se-
quences derived from H9 cells infected with vif-negative vi-
ruses (Fig. 3B), as well as to HIV-1 env clones obtained after
infection with vif-positive HIV-1 variants (Fig. 2B). Of the
non-G-to-A mutations, 41.7% were A-to-G changes, followed
by T-to-C mutations (27.2%) and C-to-T mutations (19.2%)
(Fig. 3B).
High number of HIV-1 env clones without G-to-A mutations
in PBMCs infected with HIV-1 NL4-3vif variants. Only 3 of
98 HIV-1 env sequences (3.1%) derived from H9 cells did not
show any G-to-A mutation, and one of those three clones
TABLE 1. Summary of total and G-to-A mutation frequencies of analyzed HIV-1 env clonesa
Item analyzed Cell typeinfected
No. (%) of clones, base pairs, or mutations for:
HIV-1 NL4-3 HIV-1 NL4-3vif
WT RT M184V M184I K65RM184V WT RT M184V M184I
K65R
M184V
Total no. of clones sequenced H9 29 28 23  31 34 33 
PBMC 11 13 13 6 78 105 90 68
Total no. of base pairs sequenced H9 13,514 13,048 10,718  14,446 15,844 15,378 
PBMC 5,126 6,058 6,058 2,796 36,348 48,930 41,940 31,688
Total no. of mutations H9 21 15 17  257 232 354 
PBMC 5 19 11 1 221 312 416 287
Total no. of G-to-A mutations H9 4 1 2  246 210 334 
PBMC 3 12 4 0 190 270 371 254
No. of clones without G-to-A
mutations
H9 25 (86.2) 27 (96.4) 21 (91.3)  0 2 (5.9) 1 (3.0) 
PBMC 9 (81.8) 11 (84.7) 11 (84.7) 6 (100) 29 (37.2) 40 (38.1) 33 (36.7) 36 (52.9)
Avg no. of mutations/100 bp H9 0.16 0.11 0.16  1.78 1.47 2.30 
PBMC 0.10 0.31 0.18 0.04 0.61 0.64 0.99 0.91
Avg no. of G-to-A mutations/
100 bp
H9 0.03 0.01 0.02  1.70 1.33 2.17 
PBMC 0.06 0.20 0.07 0.00 0.52 0.55 0.88 0.80
Avg no. of G-to-A mutations/
100 bp (clones without G-to-A
mutations excluded)
H9 NA NA NA  1.70 1.41 2.24 
PBMC NA NA NA NA 0.83 0.89 1.40 1.70
a WT, wild-type; , not performed; NA, not applicable.
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FIG. 3. Impact of impaired processivities of HIV-1 RT variants and the cell type on the G-to-A mutation frequencies induced by APOBEC3
proteins after infection with HIV-1 NL4-3vif variants. Shown are summarized results of two independent experiments using H9 cells and of
independent experiments using PBMCs from four different donors, A to D. Cells were infected with HIV-1 NL4-3vif, HIV-1 NL4-3vifM184V,
and HIV-1 NL4-3vifM184I. PBMCs from donors B to D were also infected with HIV-1 NL4-3vifK65RM184V. Viral DNA was isolated after the
second round of infection, and 466 nucleotides of the env gene were cloned, sequenced, and analyzed. (A) The percentages of HIV-1 env clones
carrying the indicated numbers of G-to-A mutations are shown. The numbers of clones analyzed are given. (B) Preferences of nucleotide
substitutions in HIV-1 env clones in H9 cells and PBMCs infected with HIV-1 NL4-3vif harboring different RT variants. The total numbers of
mutations are indicated. (C) Comparison of G-to-A mutation frequencies in HIV-1 env sequences harboring G-to-A mutations and generated from
H9 cells and PBMCs after infection with HIV-1 NL4-3vif, HIV-1 NL4-3vifM184V, HIV-1 NL4-3vifM184I, and HIV-1 NL4-3vifK65RM184V.
Error bars show standard deviations. WT, wild type. Asterisks represent statistical significance within both groups, i.e., H9 cell- and PBMC-derived
viral env sequences. , P  0.05; , P  0.001.
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carried an A-to-G mutation. In contrast, no G-to-A mutations
were found in 138 of 341 HIV-1 env clones (40.5%) derived
from PBMCs. This effect was slightly donor dependent. PBMCs
from donor B harbored the lowest number of HIV-1 env clones
without G-to-A mutations (9.1 to 28.6%) (Fig. 3A), and
PBMCs from donor C the highest quantity (39.3 to 73.1%)
(Fig. 3A). Overall, 51 of those 138 clones harbored different
non-G-to-A mutations, the number of identical clones harbor-
ing G-to-A mutations was low, and the results of all our control
experiments did not reveal evidence for clonal amplification or
contamination.
Finally, we compared the G-to-A mutation frequencies of
each HIV-1 NL4-3vif variant in H9 cells and PBMCs. We
observed significantly lower frequencies of G-to-A mutations
for all HIV-1 NL4-3vif variants in PBMCs than in H9 cells
(HIV-1 NL4-3vif, P 0.001, and HIV-1 NL4-3vifM184V and
HIV-1 NL4-3vifM184I, P 
 0.01) (Fig. 3C).
G-to-A mutations predominantly occur within the GG dinu-
cleotide context in viral DNA in H9 cells and PBMCs infected
with HIV-1 NL4-3vif variants. The analyzed HIV-1 env frag-
ment contains 466 nucleotides, of which 91 are guanines. We
analyzed all 290 clones derived from H9 cells and PBMCs
infected with HIV-1 NL4-3vif variants which contained G-
to-A mutations in regard to their GN dinucleotide context.
Only 6 of 13 GC and 11 of 22 GT dinucleotides were mutated
to AC and AT, respectively, at low frequencies of 0.3 to 1.0%.
In total, less than 1.5% of all G-to-A mutations occurred
within those two GN dinucleotides. GA dinucleotides, the pre-
ferred target site of APOBEC3F (7, 37, 68), were more-fre-
quently mutated to AA, accounting for 13.5% of all G-to-A
mutations. Only 1 of 31 GA dinucleotides was not mutated; 27
of 31 GA-to-AA mutations were observed with frequencies of
0.7 to 4.1%. Three GA nucleotides showed mutation frequen-
cies of 6.9, 10.3, and 12.8% (Fig. 4). However, 85.1% of all
G-to-A mutations occurred within GG dinucleotides, which is
the target site specific for APOBEC3G (6, 18, 37, 68, 69),
suggesting that the deamination of viral cDNA occurs predom-
inantly due to APOBEC3G. Twenty-two of the 25 GG dinucleo-
tides were mutated in at least 5% of the HIV-1 env clones (Fig.
4). Only three GG dinucleotides were less-frequently mutated,
and one of those GG dinucleotides was not mutated to AG in
any of the 290 clones. Nine of 25 GG dinucleotides were
mutated frequently, showing GG-to-GA mutation frequencies
of 26.9 to 71.7% (Fig. 4). No clear patterns in regard to the 5
and 3 neighboring nucleotides of GG dinucleotides appeared;
however, this might be due to the limited number of GG
dinucleotides in our HIV-1 env sequence. The G-to-A muta-
tion frequencies, which were significantly higher in viral DNA
derived from H9 cells than in PBMCs, were reflected in the
GG-to-AG mutation frequencies, which were 1.7 	 0.6 times
higher in viral DNA derived from H9 cells. However, the
pattern of frequently versus rarely mutated GG dinucleotides
was similar in both cell populations.
DISCUSSION
In this study, we have shown that the G-to-A mutation fre-
quencies in the viral genome that are induced mainly by
APOBEC3G/F are increased in HIV-1 variants expressing RTs
which exhibit low processivities. Furthermore, we discovered
that the G-to-A mutation frequencies are generally lower in
PBMCs than in the T-cell line H9.
Our HIV-1 NL4-3-derived viruses carrying different RT
variants do not exhibit different overall mutation frequencies
in the context of vif-positive viruses, either in the T-cell line H9
or in PBMCs from various donors. This is in contrast to results
obtained with purified RT enzymes carrying the M184I,
M184V, or M814VK65R mutations in cell-free nucleotide
misincorporation, mismatch extension, and M13-based for-
ward-mutation assays (13, 49, 50, 66). In these biochemical
assays, the fidelity of those RT variants was enhanced. In the
virus replication assays, the results were contradictory. Lower
fidelities of M184I and M184V variants have been observed
than for wild-type HIV-1 (14). In contrast, no differences have
been shown in regard to the fidelities of those variants and
wild-type viruses in cell cultures (24, 26). This suggests that
additional viral or cellular factors might also influence the
diversity of HIV-1.
In the context of Vif expression, G-to-A, A-to-G, and T-to-C
mutations were the most-frequent substitutions observed in H9
cells and PBMCs. This is in accordance with the results of a
large survey based on the Los Alamos HIV-1 drug resistance
database which has shown that 47% of the resistance-confer-
ring mutations are due to those three substitutions (5). In
PBMCs, we found one clone with G-to-A hypermutation,
which occurred predominantly in the context of GG dinucle-
otides and, therefore, is probably caused by APOBEC3G
deaminase activity. G-to-A hypermutation has occasionally
been detected in cell cultures infected with vif-positive HIV-1
(65). Hypermutated proviral DNA has also been detected in
patients in up to20% of sequences, predominantly in the GG
and GA dinucleotide context, without evidence of infection
with vif-deficient HIV-1 (15, 22, 29). This suggests that
APOBEC3G/F can deaminate the viral genome even in the
presence of Vif. It is also possible that Vif occasionally became
defective due to mutation(s) during reverse transcription in the
first round of infection, leading to the incorporation of
APOBEC3G/F into virions and subsequently causing G-to-A
hypermutation in newly infected cells.
In H9 cells and PBMCs infected with vif-deficient viruses, we
observed an increase in G-to-A mutation frequencies in the
viral DNA derived from HIV-1 NL4-3vifM184I compared to
the frequencies in DNA from HIV-1 NL4-3vif and HIV-1
NL4-3vifM184V. The G-to-A mutation frequencies were fur-
ther and significantly enhanced when PBMCs were infected
with HIV-1 NL4-3vifK65RM184V. These observations indi-
cate that the G-to-A mutation frequencies induced by
APOBEC3G/F are inversely correlated to the processivity of
the HIV-1 RT. It is unlikely that this is due to direct interac-
tions of the HIV-1 RT with APOBEC3G/F, because it has
been reported that the deaminase capacity of APOBEC3G
does not require the presence of the HIV-1 RT (62). Thus, it
can be assumed that RT enzymes with impaired processivities
increase the time period when viral DNA remains single
stranded and, therefore, is accessible for deaminases, like
APOBEC3G/F. In two elaborative studies, a 533 G-to-A
mutational gradient has been observed (61, 69). Yu and col-
leagues have found the highest frequencies of G-to-A muta-
tions in the 5 region of nef and the lowest in the 5 LTR (69).
A twin gradient was observed in the other study, with two
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maxima of G-to-A mutation frequencies, one at the 5 region
of nef and the second one just 5 of the central polypurine tract
(61). Those results fit nicely to the model of lentiviral reverse
transcription and demonstrate that the deamination process is
time dependent.
Our analysis of G-to-A mutation sites in regard to the GN
dinucleotide context revealed that approximately 85% of all
G-to-A mutations occurred at the first guanine of GG dinucle-
otides, although GG dinucleotides represented only 27.5% of
all four possible GN dinucleotides within the chosen 466-bp
fragment of HIV-1 NL4-3 env. GT and GC dinucleotides were
only rarely mutated to AT and AC, respectively. No differences
were observed between H9 cells and PBMCs from four differ-
ent donors. GG dinucleotides are the specific target for
APOBEC3G (6, 18, 37, 68, 69), suggesting that APOBEC3G is
mainly responsible for the G-to-A hypermutation seen in the
viral DNA of vif-deficient viruses in H9 cells and PBMCs.
Some GG dinucleotides within the analyzed part of env were
frequently mutated, whereas others were only rarely mutated.
Moreover, one GG dinucleotide was not mutated in any clone.
Remarkably, the corresponding amino acid, W427, of gp120 is
important for the binding of the viral envelope to the CD4
receptor and highly conserved among primate immunodefi-
ciency viruses (33). Here, the GG-to-AG mutation would re-
sult in a stop codon. A cytosine is positioned immediately
downstream of this GG dinucleotide. It has been shown that
G-to-A mutations do not or only rarely occur in the context of
GGC (4, 18, 34, 69). This suggests that some protective mech-
anisms against APOBEC3 protein-mediated deamination
might exist.
In all of our experiments performed with different vif-defi-
cient viruses, we have observed that the G-to-A mutation fre-
quencies were significantly higher in H9 cells than in PBMCs.
This was contrary to the expected results. It has been shown
that the replication abilities of HIV-1 variants harboring the
M184V or M184I mutation are impaired in PBMCs, which
correlates with the processivity of each RT variant. This effect
has not been observed in a T-cell line. The authors argued that
the dNTP concentrations, which are lower in primary cells than
in T-cell lines, caused the impaired replication abilities of those
HIV-1 variants in PBMCs (3). It has recently been confirmed
that a dNTP utilization defect is one reason for decreased
processivities and slower polymerization rates of HIV-1 RT
variants carrying M184I or M184A mutations, which is exac-
erbated by limiting dNTP concentrations (16). Thus, dNTP
concentrations being lower in PBMCs than in H9 cells should
lead to slower polymerization rates and subsequently to higher
frequencies of the G-to-A mutations induced by APOBEC3
proteins. In fact, we have obtained opposite results. Further-
more, on average 40% of viral env clones derived from PBMCs
did not carry any G-to-A mutation. This effect was not ob-
served to the same extent in H9 cells. Several other factors
might explain those different observations in H9 cells and
PBMCs. Recently, it has been shown that the deaminase ac-
tivity of endogenous APOBEC3G in T-cell lines and PBMCs is
lower than the deaminase activity of exogenous APOBEC3G
derived from APOBEC3G-transfected epithelial cells (64).
The authors showed that the deaminase activity of
APOBEC3G is suppressed by a yet-unidentified cellular fac-
tor(s) which is present in T-cell lines and primary CD4 cells,
but not in epithelial cells. This inhibitory activity might be
lower in H9 cells than in PBMCs, and the expression levels of
this factor(s) could vary in PBMCs from different donors. In
addition, the level of APOBEC3G/F expression might be lower
in PBMCs than in H9 cells. Variations in the level of APOB
EC3G mRNA expression have been observed in PBMCs from
different donors (23).
In regard to the high number of sequences without G-to-A
mutations in PBMCs, it is also conceivable that other antiret-
roviral mechanisms besides the deaminase activity of
APOBEC3G/F are responsible for this observation and that
those mechanisms are not similarly present and active in T-cell
lines and PBMCs from different donors. Several groups have
FIG. 4. G-to-A mutation spectrum of viral DNA in H9 cells and
PBMCs. Shown are nucleotides 7057 to 7522 of the 466-bp env frag-
ment of HIV-1 NL4-3, which was cloned and sequenced. The V3 and
V4 loops are underlined, and all first guanine residues of the GG
motifs, which are preferentially targeted by APOBEC3G, are depicted
in bold. Given in red are the percentages of guanine residues mutated
to adenine in a total of 290 HIV-1 env sequences obtained by the
infection of H9 cells (95 clones) and PBMCs from four different
donors (195 clones) harboring at least one G-to-A mutation. Percent-
ages of G-to-A mutations within GA motifs, which are the preferred
motifs of APOBEC3F, are depicted in black when more than 5% of
those motifs have been mutated.
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shown that APOBEC3G exhibits additional antiretroviral ac-
tivities; for instance, postentry restriction of HIV-1 in resting
CD4 T cells (12), inhibition of the accumulation of reverse
transcripts (17, 19, 44), and inhibition of DNA strand transfer
during reverse transcription and the integration of proviral
DNA (36, 40, 44). Another possibility might be the existence of
a population of cells within PBMCs which are susceptible to
HIV-1 infection and support virus replication but do not ex-
press APOBEC3G/F.
In summary, we have shown that the frequencies of G-to-A
mutations induced by APOBEC3G/F are increased when viruses
are expressing RT enzymes with impaired processivities. More-
over, the deaminase activity of endogenous APOBEC3G/F is
substantially lower, if not partly absent, in PBMCs than in H9
cells. Further experiments are required to explore whether this is
caused by antiretroviral mechanisms of APOBEC3G/F other
than their deaminase activity, by suppressive cellular factors in-
hibiting APOBEC3G/F, by primary cell populations not express-
ing a sufficient quantity of APOBEC3G/F, and/or for other rea-
sons.
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